NASDAQ:AKRX Akorn (AKRX) Stock Price, News & Analysis → Exposed: 10 CENT Crypto to Explode April 20th? (From True Market Insiders) (Ad) Free AKRX Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$0.09▼$0.3252-Week Range N/AVolume1.19 million shsAverage Volume9.60 million shsMarket Capitalization$3.60 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Akorn alerts: Email Address Ad Banyan Hill PublishingForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsIf you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)Watch my video for all of the details About Akorn Stock (NASDAQ:AKRX)Akorn, Inc., a specialty generic pharmaceutical company, develops, manufactures, and markets generic and branded prescription pharmaceuticals, over-the-counter (OTC) consumer health products, and animal health pharmaceuticals in the United States and internationally. The company operates in two segments, Prescription Pharmaceuticals and Consumer Health. The Prescription Pharmaceuticals segment offers generic and branded prescription pharmaceuticals in various dosage forms, including sterile ophthalmics, injectables, and inhalants; and non-sterile oral liquids, topicals, nasal sprays, and otics. Its primary products include Akten, a topical ocular anesthetic gel; AzaSite, an antibiotic used to treat bacterial conjunctivitis; Cosopt, Cosopt PF, Betimol, and Zioptan, which are used in the treatment of glaucoma; and Xopenex inhalation solution used in the treatment or prevention of bronchospasm. The Consumer Health segment manufactures and markets OTC products for the treatment of dry eye under the TheraTears brand. It also markets other OTC consumer health products comprising Mag-Ox, a magnesium supplement; and the Diabetic Tussin line of cough and cold products. In addition, this segment offers a portfolio of animal health products, such as Anased and VetaKet veterinary sedatives; Tolazine and Yobine sedative reversing agents; and Butorphic, a pain reliever. Akorn, Inc. was founded in 1971 and is headquartered in Lake Forest, Illinois.Read More Ad Banyan Hill PublishingForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsIf you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)Watch my video for all of the details AKRX Stock News HeadlinesMay 15, 2023 | thestreet.comAkorn Reaches New 52-Week High (AKRX)October 20, 2022 | businesswire.comCarlin Consumer Health Names Scott Chapman Chief Executive Officer - Business WireApril 27, 2024 | Banyan Hill Publishing (Ad)Forget AI, Imperium Is Expected to Grow 320,00% in 3 YearsIf you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)October 10, 2022 | prnewswire.comVeterinary Eye Care Market Size to record USD 788.78 Million Growth at a CAGR of 4.65% by 2026, Evolving Opportunities with Bausch Health Co Inc. And Akorn Operating Co. - Technavio - PR NewswireOctober 9, 2022 | fortune.comA small fund wagered that Elon Musk would be forced to buy Twitter—and made a killing by betting against the crowd - FortuneSeptember 29, 2022 | finance.yahoo.comDiuretic Drugs Market to Record a CAGR of 5.44%, Increasing Incidence of Hypertension Among People to Drive Growth - Technavio - Yahoo FinanceSeptember 15, 2022 | moodys.comMoody's downgrades Akorn to Caa2; revises outlook to stable from positive - Moody'sSeptember 2, 2022 | nasdaq.comPrestige Consumer (PBH) Brands & E-commerce Strength Bode Well - NasdaqApril 27, 2024 | Banyan Hill Publishing (Ad)Forget AI, Imperium Is Expected to Grow 320,00% in 3 YearsIf you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)August 29, 2022 | businesswire.comThe Worldwide Inhalation & Nasal Sprays Generic Drugs Industry is Expected to Reach $11.2 Billion by 2027 - ResearchAndMarkets.com - Business WireAugust 27, 2022 | fortune.comShort-sellers, lawyers, and academics predict the odds Elon Musk will be forced to close on a $44 billion deal he hates - FortuneAugust 26, 2022 | businesswire.comThe Worldwide Glaucoma Treatment Industry is Expected to Reach $9.1 Billion by 2027 - ResearchAndMarkets.com - Business WireAugust 26, 2022 | globenewswire.comConjunctivitis Market to Grow at a Healthy CAGR of 5.8% from 2022 to 2032 Owing to Growing Disease Prevalence Globally | Future Market Insights, Inc. - GlobeNewswireAugust 23, 2022 | law360.comWhistleblower Claims Rattle Twitter's Bid To Force Musk Deal - Law360August 17, 2022 | bloomberg.comAkorn Announces FDA-approved Generic Cetrorelix Acetate for Injection 0.25 mg - BloombergAugust 16, 2022 | prnewswire.comAkorn Announces FDA-approved Generic Cetrorelix Acetate for Injection 0.25 mg - PR NewswireAugust 11, 2022 | globenewswire.comPterygium Drug Market Trends, Shares, Key Players, Regional Overview and Market Is Growing At CAGR Of 6.2% By 2029 - GlobeNewswireAugust 5, 2022 | law360.comDelaware Powerhouse: Paul Weiss - Law360August 4, 2022 | streetinsider.comPrestige Consumer Healthcare Inc. Reports Results for First Quarter Fiscal 2023 - StreetInsider.comAugust 1, 2022 | finance.yahoo.comThe Global Animal Sedative Market is expected to grow by $ 190.96 mn during 2022-2026, accelerating at a CAGR of 5.85% during the forecast period - Yahoo FinanceJuly 26, 2022 | globenewswire.comUM6P Ventures Invests in Akorn Technology to Reduce Global Food Waste - GlobeNewswireJuly 20, 2022 | prnewswire.comBleeding Disorders Treatment Market to Receive Irresistible Growth of USD 11.65 Billion by 2029 with Size, Share Global Industry Trends, Top Players and Revenue Analysis - PR NewswireJuly 14, 2022 | law360.comIllinois Cases To Watch In 2nd Half Of 2022 - Law360July 11, 2022 | fortune.comThe fight between Musk and Twitter will come down to 3 words—and they rarely work - FortuneJuly 9, 2022 | reuters.comAnalysis: Twitter has legal edge in deal dispute with Musk - Reuters.comJune 14, 2022 | nasdaq.comPrestige Consumer (PBH) Brand-Building Efforts Solid, Costs High - NasdaqJune 10, 2022 | finance.yahoo.comThe Global Anaplastic Thyroid Cancer Drugs Market is expected to grow by $ 230.53 mn during 2022-2026, accelerating at a CAGR of 5.44% during the forecast period - Yahoo FinanceSee More Headlines Receive AKRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Akorn and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/11/2020Today4/26/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryPharmaceuticals Current SymbolNASDAQ:AKRX CUSIP00972810 CIK3116 Webwww.akorn.com Phone847-279-6100FaxN/AEmployees2,227Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.34) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-226,770,000.00 Net Margins-55.64% Pretax MarginN/A Return on Equity8.53% Return on Assets1.31% Debt Debt-to-Equity Ratio0.09 Current Ratio0.50 Quick Ratio0.32 Sales & Book Value Annual Sales$682.43 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow0.19 Book Value$1.86 per share Price / BookN/AMiscellaneous Outstanding Shares133,152,000Free FloatN/AMarket Cap$3.60 million OptionableOptionable Beta0.95 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesMr. Duane A. Portwood (Age 53)Exec. VP & CFO Mr. Joseph Bonaccorsi (Age 54)Exec. VP, Gen. Counsel & Sec. Mr. Jonathan Kafer (Age 56)Exec. VP & Chief Commercial Officer Dr. Bruce Kutinsky (Age 53)Consultant Mr. Douglas S. Boothe (Age 55)Pres, CEO & Direcor Key CompetitorsGeoVax LabsNASDAQ:GOVXPhaseBio PharmaceuticalsNASDAQ:PHASVirpax PharmaceuticalsNASDAQ:VRPXMustang BioNASDAQ:MBIOEvoke PharmaNASDAQ:EVOKView All Competitors AKRX Stock Analysis - Frequently Asked Questions How were Akorn's earnings last quarter? Akorn, Inc. (NASDAQ:AKRX) released its quarterly earnings data on Monday, May, 11th. The company reported $0.36 earnings per share for the quarter, topping analysts' consensus estimates of ($0.09) by $0.45. The business had revenue of $204.69 million for the quarter, compared to analysts' expectations of $168.90 million. Akorn had a negative net margin of 55.64% and a positive trailing twelve-month return on equity of 8.53%. What other stocks do shareholders of Akorn own? Based on aggregate information from My MarketBeat watchlists, some companies that other Akorn investors own include Integrated Device Technology (IDTI), Skechers U.S.A. (SKX), Rite Aid (RAD), Lannett (LCI), Bank of America (BAC), Quantenna Communications (QTNA), Ulta Beauty (ULTA), Paycom Software (PAYC) and Block (SQ). This page (NASDAQ:AKRX) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithBiden out June 13; Kamala won’t replace him?Paradigm PressMan Who Predicted 2008: “This Will be Worse.”AltimetryExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersA.I. is a Tidal Wave - Here’s What to BuyChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akorn, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
